Dan Nguyen
Family Medicine · Dallas, TXNPI 1952756983
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,633 of the $60,240 with a category attached, or 80.7%. Gilead accounts for 95.2% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $35,480, more than ten times the $178 reported in 2019. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $227.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$57K
- Viiv Healthcare Company$2K
- Merck$505
- Janssen Products, LP$300
- Novo Nordisk$154
- Lilly USA, LLC$106
- plus $349 from 9 others
What the payments were for
- Consulting fees$1,3902%
- Speaking & faculty fees$48,63381%
- Travel & lodging$2,0923%
- Food & beverage$7,98613%
- Education$1390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 168 | $57,323 |
| Viiv Healthcare Company | 46 | $1,503 |
| Merck | 13 | $505 |
| Janssen Products, LP | 3 | $300 |
| Novo Nordisk | 10 | $154 |
| Lilly USA, LLC | 6 | $106 |
| Johnson & Johnson | 7 | $90 |
| Theratechnologies Inc. | 3 | $80 |
| Lundbeck LLC | 2 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Pfizer | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,240 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 99 | $388,202 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $50,081 |
| ValacyclovirValacyclovir Hcl | 20 | $154 |
| Chlorthalidone | 17 | $87 |
| Atorvastatin Calcium | 27 | $79 |
| Valsartan | 11 | $53 |
| Quetiapine Fumarate | 15 | $48 |
| Lisinopril | 28 | $44 |
| Metformin Hcl ErMetformin Hcl | 14 | $29 |
| Amlodipine Besylate | 13 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $57,323 | $388,20299 claims |
| Viiv Healthcare CompanyDovato | $1,503 | $50,08118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Ashley OlsinDallas$48K
- Scott ConardDallas$41K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.